Stocktoria
LifeMD, Inc. LFMD
LifeMD, Inc. (LFMD) earns a Piotroski F-score of 5/9 (mixed financial health), with an Altman Z″ in the distress zone. It pays a dividend yielding 1.56% (safety: safe). FY2025 revenue was $194.1M at a 7.4% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Beneish M-score: -2.08 — grey zone (between the usual thresholds). A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
Smart money · insiders, last 12 months
Open-market insider purchases minus sells (SEC Form 4) — real buying with their own money is a bullish “smart money” signal; grants and option exercises are excluded.
How it ranks in Services · percentile among 982 companies
Percentile vs other Services companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 5/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | 0.146 |
| Retained earnings / assets | -3.247 |
| EBIT / assets | -0.109 |
| Equity / liabilities | 0.49 |
Sector peers · similar-size Services companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| LFMD | LifeMD, Inc. | 5/9 | -9.85 | 13.9 | +25.3% |
| SBC | SBC Medical Group Holdings Inc | 3/9 | 8.55 | 6.7 | -15.5% |
| AIRS | Airsculpt Technologies, Inc. | 3/9 | -0.63 | — | -15.8% |
| CCM | Concord Medical Services Holdings Ltd | 6/9 | -3.98 | — | +25.2% |
| TOI | Oncology Institute, Inc. | 4/9 | -5.27 | — | +27.8% |
| HIMS | Hims & Hers Health, Inc. | 4/9 | 1.61 | 61.2 | +59% |
| TDOC | Teladoc Health, Inc. | 5/9 | -16.73 | — | -1.5% |
About LifeMD, Inc.
LifeMD, Inc. operates as a direct-to-patient telehealth company, engages in the provision of patients access to virtual medical care and pharmacy services in the United States. It offers telehealth platform comprising Rex MD, a men's telehealth platform that provides virtual diagnosis, treatment, and prescription medications for men's health conditions, including erectile dysfunction, premature ejaculation, hair loss, insomnia, weight loss, and performance anxiety; and ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss. The company also provides LifeMD PC, a virtual primary care and telehealth service which is a provider for their primary care, urgent care, and chronic care needs; and offers virtual medical care, including on-demand consultations and treatment, prescription medications, diagnostics and imaging, wellness coaching, integration with in-home tools, and more. In addition, it offers GLP-1 for weight management and in-home health monitoring devices. The company was formerly known as Conversion Labs, Inc. and changed its name to LifeMD, Inc. in February 2021. LifeMD, Inc. was founded in 1994 and is headquartered in New York, New York.
FAQ
Is LFMD financially healthy?
LifeMD, Inc.'s Piotroski F-score is 5/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does LFMD pay a dividend, and is it safe?
Yes. LifeMD, Inc. pays a dividend yielding about 1.56% with a 21.6% payout ratio, rated “safe” for safety.
How profitable is LFMD?
In FY2025, LifeMD, Inc. had a net margin of 7.4% and a return on equity of 62.0%.
What is LFMD's P/E ratio?
LifeMD, Inc.'s trailing price-to-earnings (P/E) ratio is about 13.9×, based on its latest annual earnings.
What is the analyst price target for LFMD?
The average Wall-Street price target for LifeMD, Inc. is $9.88, about 200.2% above the recent price, from 8 analysts (consensus: strong buy).
Is LFMD a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on LifeMD, Inc.: a Piotroski F-score of 5/9, an Altman Z″ in the distress zone, a P/E of about 13.9×, a dividend yield of 1.56%. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.